Browsing by Author "Bulduk, Erkut Baha"

Now showing 1 - 5 of 5

Effects of Total and Subtotal Glial Tumor Resection on Survival
(2020) Ercan, Serdar; Ataizi, Zeki S; Ataizi, Fulya; Bulduk, Erkut Baha; Surgical Sciences; 08. Medical School; 01. Atılım University
Objectives: Glial tumors are treated with a multidisciplinary team approach including specialists in brain surgery, radiology, pathology, radiation oncology and medical oncology. Surgery is one of the main treatment options. However,the effect of resection volume on prognosis is still uncertain. The aim of this study is to investigate the relationshipbetween the residual tumor volume and survival of the patients who were operated with the diagnosis of intracranialglial tumor in the last 5 years.Methods: Of 49 patients, 30 underwent total resection and 19 underwent subtotal resection.Results: The average surveys of total resection were 13.6 (6-32 months) months. 4 of 6 patients with anaplastic astrocytoma survived and the mean survey was 26.5 (4-45) months. The survey of subtotal resection group was significantlyshorter than the other TR group.Conclusion: As a result, recovery was inversely increased with residual tumor volume
Efficacy of Gamma-Knife Radiosurgery in Grade 2 and Grade 3meningioma: a Single-Center, Long-Term Follow-Up Study
(2021) Bulduk, Erkut Baha; Demirci, Harun; Karaaslan, Burak; Demirtaş, Oğuz Kağan; Emmez, Ömer Hakan; Kurt, Gökhan; Surgical Sciences; 08. Medical School; 01. Atılım University
Objectives: Gamma-Knife Radiosurgery (GKR) is a safe and effective treatment option in patients who have a high riskof complications in skull base and eloquent area-based tumors, in those to whom total surgery cannot be applied. Thepurpose was to analyze the results of radiosurgery in patients who underwent GKR for the residues or recurrent tumorsin high grade meningiomas. Methods: A retrospective screening was performed on patients who underwent GKR at Gazi University between 2004and 2018. The gender, mean age, location, volume, complications, size changes after GKR were noted. Results: A total of 35 (79.5%) patients were treated with Grade 2, and 9 (20.5%) were treated with Grade 3 meningio mas. The mean follow-up period was 48 months (3-108). The mean volume was noted as 9339 mm3 . The tumor controlrates after GKR were determined as 94% in Grade 2 and 55% in Grade 3 meningiomas. Conclusion: GKR can be applied as a safe and effective method for postoperative tumor control in high grade meningiomas.
Citation - WoS: 4
Citation - Scopus: 4
Neuroprotective effects of adrenomedullin in experimental traumatic brain injury model in rats
(Turkish Assoc Trauma Emergency Surgery, 2022) Emmez, Gokcen; Bulduk, Erkut Baha; Yildirim, Zuhal; Surgical Sciences; 08. Medical School; 01. Atılım University
BACKGROUND: Traumatic brain injuries cause damages in the brain in several ways, which include cell death because of edema, disruption of the blood-brain barrier, shear stress, and ischemia. In this study, we investigated the effects of adrenomedullin (AM) on oxidative stress and inflammation after head traumas in a rat model. METHODS: Eighteen male adult Wistar albino rats were randomized into three groups (n=6). No traumas were applied to the control (C) group. Traumas were applied in line with Marmarau trauma model in the trauma group. The rats in the AM treatment group were treated with post-traumatic 12 mu g/kg i.p. AM in addition to the trauma group. The rats were followed for 7 days in all groups and were then sacrificed. Brain tissues and blood samples were taken. RESULTS: In the trauma group, both tissue and serum MDA, TNF-alpha, and IL-6 levels were significantly increased compared to the control group (p<0.05). In the AM-treated group, serum TNF-alpha levels were significantly decreased compared to the trauma group (p<0.05). In the trauma group, both tissue and serum GSH levels were significantly decreased compared to the control group (p<0.05). In the trauma group, serum Vitamin D3 levels were significantly decreased compared to the control group (p<0.05). In the AM-treated group, both tissue and serum GSH levels were significantly increased compared to the trauma group (p<0.05). CONCLUSION: These results indicate that AM has neuroprotective effects on traumatic brain injury in a rat model.
Citation - WoS: 6
Citation - Scopus: 7
Stereotactic Radiosurgery After Subtotal Resection of Critically-Located Grade I Meningioma: a Single-Center Experience and Review of Literature
(Turkish Neurosurgical Soc, 2021) Karaaslan, Burak; Celtikci, Emrah; Bulduk, Erkut Baha; Borcek, Alp Ozgun; Kurt, Gokhan; Kaymaz, Memduh; Emmez, Hakan; Surgical Sciences; 08. Medical School; 01. Atılım University
AIM: To analyze the results of stereotactic radiosurgery in 295 patients with residual Grade I meningiomas located at parasellar region, petroclival region, cerebellopontine angle and parasagittal region. MATERIAL and METHODS: A total of 295 patients with Grade 1 residual Meningiomas (197 women, 98 men), who were treated by adjuvant radiosurgery in Gazi University Gamma Knife Center between 2004-2015 were analyzed. WHO Grade 2 and 3 meningiomas were not included in our study. Minimum radiological follow-up was 24 months. The median follow-up was 54 months. The tumor volume, location, treatment dose, morbidity, progression free survival and tumor control rate were analyzed. RESULTS: The median tumor volume was 5.2 cm(3) (0.04-39.7), median age was 50 (20-80), median dose was 14 Gy and tumor control rate was 94.5% (stationary in 85.0%, volume reduction in 9.5%). Increase in tumor volume was seen in 16 patients (5.5%) and re-operation was performed in 5 of them (1.6%). Stereotactic radiosurgery was performed again for 8 patients (2.7%).The location of the tumors was as follows: 39.3% parasellar region, 20% cerebellopontine angle, 13.6% petroclival and 27.1% was parasagittal, falcine or convexity. Major morbidities were detected in 6 (2%) patients. Minor morbidities were detected in 18 (6.1%) patients. CONCLUSION: Stereotactic radiosurgery is an effective and safe treatment modality for residual Grade I meningiomas.
Citation - WoS: 4
Citation - Scopus: 3
Thioredoxin System and Mir-21, Mir-23a/B and Let-7a as Potential Biomarkers for Brain Tumor Progression: Preliminary Case Data
(Elsevier Science inc, 2022) Kilic, Nedret; Boyacioglu, Ozge; Saltoglu, Gamze Turna; Bulduk, Erkut Baha; Kurt, Gokhan; Korkusuz, Petek; Basic Sciences; Surgical Sciences; 08. Medical School; 01. Atılım University
BACKGROUND: The thioredoxin system and microRNAs (miRNAs) are potential targets for both cancer progression and treatment. However, the role of miRNAs and their relation with the expression profile of thioredoxin system in brain tumor progression remains unclear. METHODS: In this study, we aimed to determine the expression profiles of redox components Trx-1, TrxR-1 and PRDX-1, and oncogenic miR-21, miR-23a/b and let-7a and oncosuppressor miR-125 in different brain tumor tissues and their association with increasing tumor grade. We studied Trx-1, TrxR-1, and PRDX-1 messenger RNA expression levels by quantitative real-time polymerase chain reaction and protein levels by Western blot and miR-23a, miR-23b, miR-125a, miR-21, and let-7a miRNA expression levels by quantitative real-time polymerase chain reaction in 16 glioma, 15 meningioma, 5 metastatic, and 2 benign tumor samples. We also examined Trx-1, TrxR-1, and PRDX-1 protein levels in serum samples of 36 patients with brain tumor and 37 healthy volunteers by enzyme-linked immunosorbent assay. RESULTS: We found that Trx-1, TrxR-1, and PRDX-1 presented high messenger RNA expression but low protein expression in low-grade brain tumor tissues, whereas they showed higher protein expression in sera of patients with low-grade brain tumors. miR-23b, miR-21, miR-23a, and let-7a were highly expressed in low-grade brain tumor tissues and positively correlated with the increase in thioredoxin system activity. CONCLUSIONS: Our findings showed that Trx-1, TrxR-1, miR-21, miR-23a/b, and let-7a might be used for brain tumor diagnosis in the clinic. Further prospective studies including molecular pathway analyses are required to validate the miRNA/Trx system regulatory axis in brain tumor progression.